首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   856708篇
  免费   71229篇
  国内免费   1811篇
耳鼻咽喉   12807篇
儿科学   24580篇
妇产科学   25146篇
基础医学   123230篇
口腔科学   25473篇
临床医学   75064篇
内科学   162831篇
皮肤病学   16956篇
神经病学   69600篇
特种医学   35223篇
外国民族医学   171篇
外科学   135700篇
综合类   24600篇
一般理论   266篇
预防医学   66503篇
眼科学   20490篇
药学   64580篇
中国医学   1579篇
肿瘤学   44949篇
  2018年   7333篇
  2015年   7737篇
  2014年   11140篇
  2013年   16814篇
  2012年   22754篇
  2011年   23881篇
  2010年   13885篇
  2009年   13087篇
  2008年   22570篇
  2007年   24618篇
  2006年   24506篇
  2005年   24147篇
  2004年   23710篇
  2003年   22827篇
  2002年   21924篇
  2001年   35788篇
  2000年   36411篇
  1999年   30660篇
  1998年   8684篇
  1997年   7903篇
  1996年   7820篇
  1995年   7945篇
  1994年   7668篇
  1992年   26646篇
  1991年   26127篇
  1990年   25631篇
  1989年   24687篇
  1988年   23226篇
  1987年   22895篇
  1986年   21749篇
  1985年   21114篇
  1984年   16385篇
  1983年   13958篇
  1982年   8832篇
  1981年   8167篇
  1980年   7631篇
  1979年   16697篇
  1978年   12077篇
  1977年   10144篇
  1976年   9295篇
  1975年   10113篇
  1974年   12617篇
  1973年   12118篇
  1972年   11526篇
  1971年   10670篇
  1970年   10197篇
  1969年   9899篇
  1968年   8894篇
  1967年   8213篇
  1966年   7641篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Cognitive Therapy and Research - Despite interest in psychological inflexibility as a marker of suicide risk, no measure of psychological inflexibility specific to SI exists. The present study...  相似文献   
4.
5.
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is imperfect with one-third of low-risk patients developing disease resistance to first-line single-agent chemotherapy. We aimed to generate simplified models that improve upon FIGO. Logistic regression (LR) and multilayer perceptron (MLP) modelling (n = 4191) generated six models (M1-6). M1, all eight FIGO variables (scored data); M2, all eight FIGO variables (scored and raw data); M3, nonimaging variables (scored data); M4, nonimaging variables (scored and raw data); M5, imaging variables (scored data); and M6, pretreatment hCG (raw data) + imaging variables (scored data). Performance was compared to FIGO using true and false positive rates, positive and negative predictive values, diagnostic odds ratio, receiver operating characteristic (ROC) curves, Bland-Altman calibration plots, decision curve analysis and contingency tables. M1-6 were calibrated and outperformed FIGO on true positive rate and positive predictive value. Using LR and MLP, M1, M2 and M4 generated small improvements to the ROC curve and decision curve analysis. M3, M5 and M6 matched FIGO or performed less well. Compared to FIGO, most (excluding LR M4 and MLP M5) had significant discordance in patient classification (McNemar's test P < .05); 55-112 undertreated, 46-206 overtreated. Statistical modelling yielded only small gains over FIGO performance, arising through recategorisation of treatment-resistant patients, with a significant proportion of under/overtreatment as the available data have been used a priori to allocate primary chemotherapy. Streamlining FIGO should now be the focus.  相似文献   
6.
7.
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible.  相似文献   
8.
Die Anaesthesiologie - Der Mangel an automatischen externen Defibrillatoren (AED) und die fehlende Kenntnis von Ersthelfern im Umgang mit diesen Geräten haben in Deutschland zu einer...  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号